Corcept Therapeutics (CORT) Tops Q2 EPS by 35c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $85.86 -20.13%
Revenue Growth %: +56.0%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +56.0%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $256.1 million versus the consensus estimate of $217.85 million.
FY 2026 Outlook:-
Revenue between $1.1 billion – $1.2 billion vs consensus $999.5 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- FDA approves first once-weekly insulin for type 2 diabetes mellitus in pediatric patients
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
